Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Detection Technology, Financial statements review 2025

By Inderes2/5/2026, 11:00 AM
Detection Technology

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Hannu Martola
00:00 - 11:09

From Detection Technology, and welcome to follow its fourth quarter results announcement. I'm pleased to be presenting it to you. Fourth quarter net sales reached €29.7 million, a 6% decrease. EBITDA was €3.7 million, and the EBITDA percentage was 12.44%. So, it was approximately 1.5 million below what we achieved last year. The biggest reason for the sales decline was the currency exchange rate, which represents about 5.5%. So without that, the sales would be very much flattish. But we'll be explaining a bit closer what took place. So, looking at the applications point of view, sales in Medical developed quite well. But then in security declined. Industrial sales were 7% negative, but there was very strong growth in flat panels. TFT was even 50% for the quarter and actually for the full year, 60% growth. This was driven especially by battery inspection in APAC. And then line-scan sales were declining, while medical sales grew by 19%, showing very strong growth driven by CT. And also the healthcare reform in China is now in action. And that is then also driving the growth in China. Security -29% looks a bit harsh. Big number. But actually, this is very much an outcome of certain one-time events. And also, we must remember that the fourth quarter in 2024 was fairly high, exceptionally high in security, as well as in 2023. So, there's some seasonality involved, and the biggest single item for the decline in security was the European 100ml effect. The European 100ml Liquid Rule effect was still affecting the fourth quarter. Now it's past. Also, we had fairly sizable inventories with a couple of customers. And that's now also past. And then also relating to security. The market was very soft, especially in China. Typically, the fourth quarter is the best. However, this year, 2025, sales saw a 6% decline compared to the previous year, which also resulted in lower profitability. So with smaller sales and especially the sales very much focusing on Medical, where profitability is lower, this affected the overall outcome. We had 12.4% EBITDA. From a market point of view. AMERICAS was flattish. APAC. APAC declined by 4.4%. Despite that, the medical was strong there. But then on the other side, security and industrial were weaker. And then Europe, down 12%, clearly driven by the security point; it is worth noting here that precisely two-thirds of our sales are in APAC. And the economies in APAC actually grow at double the rate compared to those in the Western world. This is a good position to have. Then, from an application point of view, Industrial was down, Medical was up 19%, and Security was down almost 30%. And here, clearly, you can see that medical is representing 50% of sales. And that's exceptional if you look also in our history. For the full year, net sales were 101 million, down 6%. EBITDA was 9.6 million, representing 9.55%. Actually, the biggest impact there is the currency exchange rate that affects more than half of this decline. Full year AMERICAS -22% APAC flat, EMEIA -16%. And both EMEIA and AMERICAS, by the way, are driven by the weak security segment performance. Looking then more closely at the finances. EBITDA 3.7 versus last year 5.2. EBITDA for the full year was €12.4 million compared to €6.6 million last year, and EBIT for Q4 was €1.3 million. We did not have any non-recurring items. So this is clear from that point of view. And also I want to highlight that we are recognizing all R&D as cost. So the full R&D spending, which clearly is an investment but it's not capitalized. So, as a cost, it was €2.8 million, and for the full year, it was €11.3 million, representing 11.2% of our sales. Cash flow was down quite sizably. And the reason there is that we are on purpose, we have been increasing our inventories to be ready for supporting the growth in the challenging global markets, where actually there are sudden shortages of materials. For example, investments were quite reasonable, reaching $900,000 for the quarter and $2.3 million for the full year, and then the return on investment. Still quite okay, 9.2%, and the earnings per share were €0.22 for the quarter. We just launched our Deetee 2030 strategy in November in our Capital Markets Day. As a reminder, our target is to outgrow the market. The market grows 3%. We aim to have 10% market share and to provide higher value-added, data-generating X-ray detectors through outstanding interfaces, usability, and services for our customers. Markets are driven by aging populations, security concerns, quality and efficiency, eco and circular economies, shortage of raw materials, and overall, machine learning, AI, and digitalization are driving the use of detectors. You can learn much more what's going on through clever use of AI. Out of the markets, clearly the biggest by application is healthcare at 70%. And then, security and industrial, representing a bit over 10% of the market, by technology, DT is strongest in line scan and CT, which are fast and very precise scanning methods. We are market leaders there. And then the TFT panel market, which is a more static part of the digital X-ray market, represents 40%, making it the biggest at almost 1.5 billion out of the 3 billion estimated market for 2030. So we now have a very good position. Our business for the future will be more balanced because we have good products for all of these various technologies and applications. Strategy. In a nutshell, we are building on top of high-performing people through excellent customer interface. And the four cornerstones are the improvements in basic operations; R&D becoming faster, more productive, and increasing overall productivity; marketing and selling; and building TFT panels not only in China. Where our growth has clearly been strongest so far, but then also globally adding value to our products, being active with customers, finding ways how we can also build up software capabilities with them, and all is typically built on top of our hardware. And then we are looking for the new technology like Photon counting for the 2030 and beyond. As an example, we are looking back last year at what we achieved. The big things: in the middle, you see the heart. That's India. So we actually had the inauguration of the India factory in December. And now we are ready to provide locally made products for Indian markets. We were awarded a very important recognition. GE Healthcare is the number one in the healthcare industry, highly reputable. And we were selected out of more than 20,000 suppliers as GE's Supplier of the Year. By the way, spending about 10 billion into their sourcing. So this is a sizable recognition. And then we developed a new Photon counting CT detector and associated data management solutions, also creating a new low-cost product, AVA, for line-scan applications, and focusing on sustainability. We were awarded Ecovadis bronze with a score of 63. And by the way, only about 2% of the companies applying and being awarded this reach bronze or better. So this is a very good position to start. Sales expectations. Now, for the first quarter and first half, I think we are full of energy and looking positively, because we have a quite nice outlook for the first quarter. We see that all our applications are growing: Industrial, Medical, and Security. All our regions. We are officially guiding double-digit growth, not only for the first quarter, but also for the first half of this year. Regarding the dividends, the board is proposing a €0.30 dividend, which represents 68% of the net proceedings. The financial targets remain the same: at least 10% growth and at least 15% of EBITA, and the dividend percentage is between 30% to 60% of net proceeds as guidance. I have a couple of questions. I'm very happy and pleased to answer any questions you might have.

Nick
11:11 - 11:38

This is Nick from CIB. I have a couple of questions. Starting with a technical question, regarding the earlier technical problem, you are guiding double-digit sales growth now in Q1, and the FX seems to be quite negative still in Q1. If we look at the current rates. So what kind of FX impact are you baking into your guidance there.

Hannu Martola
11:38 - 12:03

The FX is based on today's rates. Yes, that's true. If we look at the comparable last year's quarter, I think for us, we would probably have -5% just with the same amount of sales. So that has been taken into account. So the numbers we are reporting, we are saying that we are at least 10% higher for the first quarter.

Nick
12:05 - 12:05

Regarding the dividends, the board is proposing a €0.30 dividend, which represents 68% of the net proceedings.

Hannu Martola
12:05 - 12:12

So, the comparable growth would be 15% higher if the FX impact were five percentage points.

Nick
12:13 - 13:09

Regarding the dividends, the board is proposing a 30-cent dividend, which represents 68% of the net proceedings. Then, regarding the business areas or applications, particularly the medical business. So your sales grew quite nicely in the medical business in Q4. But was that driven by bigger deals, clients refilling their inventories, or end markets improving? And I guess that similar kind of a question, what are you expecting in your guidance for Q1/H1? And then maybe to give a bit more color on that, as the big Western OEMs working in China still seem to be quite cautious on China sales in 2026. So could you give kind of a guide or color on maybe your different view.

Hannu Martola
13:10 - 14:00

We have not seen any sort of change that some customers would be buying to inventory or so on. So the behavior has been that they are selling about the same amount. For medical, China is actually the most important market because it is the hub in the world. Typically companies export about 50% of their volume that they make in China. So 50% stays in the country, 50% goes out on average. So there's a lot of export out of the markets. And I think now after the Chinese healthcare system and its new processes have been in place for some time. So there are some more activities going on there. And then we see growth in that market too, but also globally.

Nick
14:01 - 14:21

Typically, companies export about 50% of their volume that they make in China. But you've said earlier that now, after the reform in China. So basically, the business there will be a bit more lumpy, or the sales may come in bigger chunks. So, is this a case of that kind of thing, or do you just see the business continuing?

Hannu Martola
14:22 - 14:47

I think it was. That's a very good question. Thanks. I think at the beginning, after the markets started to open up after the reform, it was probably a bit more lumpy due to companies and customers being more careful. Now when it's been in place for some time. So it is a little bit balancing. And also, the customers can count that they get business.

Nick
14:49 - 15:13

We don't separate that; industrial is industrial. I think it was. Then one last from me and related to the industrial business where you showed nice growth in TFT business, but that also indicates that the legacy business was quite much down. So, can you comment on that and what kind of expectations do you have for Q1 / H1 for the legacy business in industrial?

Hannu Martola
15:13 - 15:59

We don't separate that; industrial is industrial. But as for the fourth quarter sales. Yes. TFT was positive, and industrial battery clearly drove that growth. I think food scanning also was growing; the basic industrial line scan was not growing, especially in China. The outlook for the first quarter, I think overall in industrial is very positive. It should even be the legacy. Let's see how it moves. But most important is that we will have growth for the industrial part.

Nick
15:59 - 16:04

So that there isn't any bigger structural problem in industrial legacy business.

Hannu Martola
16:05 - 16:18

No. I think industrial business in China is just highly competitive. So it's cutthroat competition, and everybody is fighting for even very small deals.

Nick
16:19 - 16:22

Even for the legacy. I understand that's all from me. Jonas from Evli.

Jonas
16:25 - 16:55

Jonas from Evelyn. If I can come back to this 15% underlying growth you said you see in H1, can you elaborate on the components in terms of volume and pricing, how it looks from those perspectives. And it's also possible to elaborate from the perspective of the product application area. So how are volumes developing on the one hand, and how is the pricing, especially within medical, where there are still probably some pricing headwinds?

Hannu Martola
16:55 - 16:59

You mean pricing from us to our customers or pricing from our materials?

Jonas
16:59 - 17:02

Well maybe both.

Hannu Martola
17:02 - 18:16

Basically, regarding pricing, and just to be a bit more specific. So, we must remember that the big currency exchange happened in March after Trump implemented his tariff policies. So, actually, the currency headwind or about 5% effect is only for the first quarter. So, for the second quarter, then, at least from today's point of view, the currencies are very much in line with those of the comparable quarter. Then, regarding pricing, almost all of our pricing is fixed for this year. So in a way, we know that yes, there have been some challenging negotiations and so on. And those are included in our plans relating to materials. And of course, I don't think there have been any sizeable inflationary effects. But also we must remember that we have been able to reduce costs by bringing certain value-added processes to our own factory in Wuxi, and that has helped us to reduce the costs.

Jonas
18:17 - 18:24

So to summarize, basically pricing relatively flat. So it's mostly volume growth that you're expecting in Q1.

Hannu Martola
18:25 - 18:36

And yes, very much is volume growth. Yes, there are also some price reductions. And so, in light of the competition, these are the ongoing developments. But volume is the key player there.

Jonas
18:37 - 19:05

And can you? What are your thoughts on the security performance in Q4? Because to me, it seems that sales declined perhaps faster than you might have expected. So, are you now seeing very much more or can you say something more specific about security in Q1? What kind of recovery in revenue are you seeing?

Hannu Martola
19:06 - 19:40

Security in Q1 is very much driven by CT, so. That's good. It was not driven by CT last year. So, I think from that perspective, I understand the numbers look strange, but there are some one-time effects and so on. And we have not lost any customers or faced any significant issues. It's just some delays and some inventory affecting until it starts to pull and sells through.

Jonas
19:41 - 20:09

Right. And maybe still on Q4 earnings. Arguably, you might say that it was even a relatively strong result considering the rather unfavorable product mix. So, are you happy, given that your gross margin still declined by some 350 basis points year on year because of this unfavorable product mix? But are you now happy with these margins and costs you saw in Q4?

Hannu Martola
20:09 - 20:55

I cannot be happy because we didn't deliver our numbers. So, clearly we were behind in sales and profits. And of course, there are reasons and explanations there, and so on. But what I'm happy about from last year, 2025, is that I think we were quite successful in building a good foundation. How to step up. We launched 60 new products in TFT, new products also in our legacy business and so on. And we achieved certain things like the GE Supplier of the Year award and these kinds of things. So those clearly show that as a team, we perform, we can deliver, customers trust us, and we can move forward and build growth.

Jonas
20:55 - 20:57

And so, because of the competition, what is happening? What do you think about the security performance in Q4? That's all from me.

Patrick Campbell
21:01 - 21:11

Hi. It's Patrick Campbell from Nordea. I'm just going back to the inventories. You mentioned that you've increased inventories. Could you please explain the reasoning behind this?

Hannu Martola
21:12 - 22:22

We have practically two reasons. One is that we are having some change in some suppliers. That means that we have to prepare for the transition period. We must be sure that we have the materials. And until we have approvals and everything clear. And then the other side is that we are preparing also for the coming growth. We clearly see that, for example, data centers driven by AI have really changed the supply-demand picture in the world. And there are certain active components and semiconductors that were quite easy to get. Those are now really, really hard. Luckily we don't have memory chips in our products, which is probably one of the areas that is really, really facing shortages. So we are preparing so that even if there's some headwind and some challenges on availability, we still can support our customers and have the materials and components to grow.

Patrick Campbell
22:23 - 22:34

Just a follow up on that topic, how well would you describe your coverage for the full year and then what kind of costs are you expecting from these supplier changes?

Hannu Martola
22:36 - 22:55

The costs are in our plans. What we need to do is make sure that we can deliver on our target, which is minimum 10% growth. And that's something that we are preparing ourselves.

Patrick Campbell
22:57 - 22:57

We have practically two reasons.

Juha Kinnunen
23:02 - 23:20

We have Juha Kinnunen from Inderes Online. So we could be taking a few of his questions next. Yeah. So just commenting that you had a solid growth in TFT sales. So could you comment on the growth outlook a bit further in different areas such as industrial, medical, and defense?

Hannu Martola
23:22 - 24:01

Yes. I mean, TFT growth, we were able to win two super important and big customers who are driving this growth, which also is then a clear sign that we are competitive. We are competent and competitive as a supplier, meeting high quality and cost targets. And this will help us to grow also in other areas for other customers. And if you can do it in China, then the markets in Europe and the US are not that competitive.

Juha Kinnunen
24:03 - 24:11

Okay. Thank you. What kind of sales growth do you expect from the defense sector, and is it coming from Europe?

Hannu Martola
24:12 - 24:49

The defense sector? Typically, our products in the defense sector are used in what we call industrial nondestructive testing. There are customers out there making big systems who are scanning and checking through engine blocks, cylinder blocks, or aerospace engines, as well as for military and defense applications. And there are possibilities to grow not only in Europe but also, for example, in the US.

Juha Kinnunen
24:51 - 24:58

What kind of sales growth do you expect from the defense sector and is it coming from Europe? Still, one question for you. So how do you expect your gross margins to develop in 26?

Hannu Martola
24:59 - 25:21

Probably gross margins. If we are discussing sales materials and what remains, we will probably see similar performance to what we had in 2025. That's highly dependent. How will the product mix turn out?

Juha Kinnunen
25:22 - 25:24

And there are possibilities to grow not only in Europe but also, as an example, in the US. No further questions.

Nick
25:27 - 25:47

Hello, this is Nick from CBA again. I will have one additional question. You highlighted in your report that changes in your client portfolio affected your business in 25. So are those impacts now over going into 26?

Hannu Martola
25:49 - 26:07

We were somewhat affected by 2025 profitability, as we experienced the end-of-life for the analog portfolio. And that's then behind us. From today's point of view, we don't see any significant changes in that area other than that.

Nick
26:08 - 26:09

What kind of sales growth do you expect from the defense sector, and is it coming from Europe? Thanks.

Hannu Martola
26:11 - 26:26

Thank you. Are we done with the questions? Okay. And there are possibilities to grow not only in Europe but also in the US. Thank you everybody and look forward to delivering on the first quarter and first half with our team. Thank you. Goodbye.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…